Neoplasm.News

BRAF inhibitor × Dermatologic × Clear all

4 Announcements

FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation

Drugs: Tafinlar (dabrafenib) · BRAF inhibitor, Mekinist (trametinib) · MEK inhibitor, trametinib is not indicated · MEK inhibitor
Condition: Other solid neoplasm

FDA approves atezolizumab for BRAF V600 unresectable or metastatic melanoma

Drugs: Tecentriq (atezolizumab) · Anti-PD-L1 antibody, cobimetinib · MEK inhibitor, vemurafenib · BRAF inhibitor
Condition: Dermatologic

FDA approves encorafenib and binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations

Trial: COLUMBUS
Drug: BRAFTOVI and MEKTOVI (encorafenib and binimetinib) · BRAF inhibitor
Condition: Dermatologic

FDA approves dabrafenib plus trametinib for adjuvant treatment of melanoma with BRAF V600E or V600K mutations

Trial: COMBI-AD
Drugs: TAFINLAR (dabrafenib) · BRAF inhibitor, MEKINIST (trametinib) · MEK inhibitor
Condition: Dermatologic